Long-term efficacy and safety of nonablative monopolar radiofrequency in the treatment of moderate to severe acne vulgaris

The efficacy and safety of monopolar radiofrequency for treatment of moderate-to-severe recalcitrant acne

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220627002

Enrollment

Registered

2022-06-27

Start date

2022-06-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with moderate to severe recalcitrant acne monopolar radiofrequency, moderate to severe recalcitrant acne

Interventions

Patient were treated with monopolar radiofrequency 2 sessions every 4 weeks. Then they were instructed to follow up at 1, 3, 6, 9, and 12 months after the final treatment.

Experimental Device

Monopolar radiofrequency

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 years or older 2. Were diagnosed with moderate to severe recalcitrant acne by dermatologist 3. The patient who were not responded by standard treatment, for example, topical treatments and oral antibiotics at least 3 month and have to hold any treatment for 1 month

Exclusion criteria

Exclusion criteria: 1. Patients who are pregnant, lactating, and postpartum within 1 year 2. Patients who taking oral isotretinoin within 1 year 3. Patients with other skin disease, or having infection at the area of face 4. Immunocompromised patients 5. Patients with hypertrophic scar or keloid 6. Patients with history of Cushing syndrome or Ehlers-Danlos syndromd 7.Patients with cancers or skin cancers 8.Patients with mental disorders 9.Patiens with chemical peels within 1 month 10. patient with herpes simplex infection

Design outcomes

Primary

Measure	Time frame
Investigator Global Assessment (IGA) Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment Antera,Acne count Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment Counting	—

Secondary

Measure	Time frame
Sebum level Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment Sebumeter,Pain score Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment Visual Analog Scale,Safety Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment Adverse events,Dermatology Life Quality Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment DLQI	—

Measure

Time frame

Sebum level Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment Sebumeter,Pain score Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment Visual Analog Scale,Safety Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment Adverse events,Dermatology Life Quality Baseline; 1 month after first treatment; 1, 3, 6, 9, and 12 months after second treatment DLQI

—

Countries

Thailand

Contacts

Public ContactWoraphong Manuskiatti

Faculty of Medicine Siriraj Hospital, Mahidol University.

woraphong.man@mahidol.ac.th664194333

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026